Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone long-acting injectable for recurrence prevention in bipolar I disorder
2006-001490-15Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risperidone in bipolar I disorder (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Time to recurrence of any mood episode and Recurrence with a mood episode. Started Aug 2006; status: completed.
02
Drugs
risperidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2006-001490-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001490-15.